Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Legg Mason Starts Hollis-Eden Pharmaceuticals with 'Sell'


Legg Mason initiated coverage on Hollis-Eden Pharmaceuticals (HEPH) with sell.

Analyst Edward Nash says if the company is unable to secure a government contract for its lead product candidate Neumune (HE2100) -- a radioprotectant in development through a collaborative research agreement with the government -- shares will be negatively affected. He says, with the exception of Neumune, the company's pipeline is in an extremely early stage; he doesn't think Hollis-Eden will realize any revenue in the near future for product candidates.

Nash says Hollis-Eden trades at a 216% premium to the median technology value of peers. He set a $10 target, and sees a $1.35 2003 loss per share.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus